Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Jack Jample Ant Ant Venom Immunothérapie à long terme Investigation (JAVELIN)

29 septembre 2026 mis à jour par: Murdoch Childrens Research Institute

Jack Jumper ant (JJA) venom allergy is a uniquely Australian medical condition. It is the leading cause of venom allergy and affects up to three per cent of the population. 70 percent of people with JJA allergy will have another reaction on a repeat sting and this sensitivity appears to persist for many years.

Venom immunotherapy (VIT) has been shown to be a safe and effective treatment in the prevention of severe systemic allergic reactions (anaphylaxis) to future stings. It is currently offered to patients as standard care in Tasmania, South Australia and Victoria. However, whilst JJA VIT has been used for many years, there is a lack of evidence on the long-term benefit of the treatment and how it impacts patient quality of life.

This trial will offer patients who have completed a JJA VIT program (between 3 and < 6-years duration) and have been off-treatment for at least 18-months and < 5 years, to have a supervised JJA sting challenge and blood test to assess their JJA venom tolerance level. It will also ask them to complete a set of questionnaires at different timepoints to obtain a history of their exposure and reactions to JJA stings outside of the hospital setting (field stings), and to measure the impact of the completed VIT and knowledge of their sting challenge outcome on their quality of life and their behaviours around auto-injectors.

These measures will be used to explore the long-term effectiveness of JJA VIT and the impact of a sting challenge post VIT on a patient's quality of life.

Aperçu de l'étude

Statut

Recrutement

Description détaillée

This will be a prospective, multicentre, phase 4 clinical trial examining the long-term effectiveness (measured by response to an in-hospital JJA sting challenge, primary outcome) and impact on quality of life of JJA VIT involving 3 Australian tertiary hospital sites offering this treatment - Royal Hobart Hospital, Royal Adelaide Hospital and Monash Medical Centre.

Patients who have completed their JJA VIT (between 3 and <6 years duration) at one of the 3 sites and off-treatment for at least 18 months and < 5 years, will be invited to participate in the trial by their original treating site. A research team member will obtain informed e-consent and a booking for an in-clinic JJA sting challenge will be allocated. For all consented participants, quality of life (QoL), anxiety and depression scores, history of field sting reactions since treatment completion and attitudes toward adrenaline autoinjector carriage/usage will be collected via questionnaire at trial enrolment, sting challenge, 1-month post sting challenge and annually for 3-years. A blood sample will be collected immediately prior to the sting challenge at the in-clinic appointment. Participants will also be asked to consent to access retrospective data related to their completed JJA VIT course from their hospital clinical records.

Optional consents will also be sought from each participant for the collection of an extra tube of blood with the serum biobanked for future analysis, and the inclusion of their data in the National Allergy BioRepository (ALBI).

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: National Allergy Centre of Excellence
  • Numéro de téléphone: 61 3 99366752
  • E-mail: nace@mcri.edu.au

Lieux d'étude

    • South Australia
      • Adelaide, South Australia, Australie, 5000
        • Recrutement
        • Royal Adelaide Hospital
        • Contact:
          • National Allergy Centre of Excellence
          • Numéro de téléphone: 61 3 99366752
          • E-mail: nace@mcri.edu.au
        • Chercheur principal:
          • Carlo Yuson, MD FRACP
    • Tasmania
      • Hobart, Tasmania, Australie, 7000
        • Recrutement
        • Royal Hobart Hospital
        • Contact:
          • National Allergy Centre of Excellence
          • Numéro de téléphone: 61 3 99366752
          • E-mail: nace@mcri.edu.au
        • Chercheur principal:
          • Troy Wanandy, PhD
    • Victoria
      • Clayton, Victoria, Australie, 3168
        • Recrutement
        • Monash Medical Centre
        • Contact:
          • National Allergy Centre of Excellence
          • Numéro de téléphone: 61 3 99366752
          • E-mail: nace@mcri.edu.au
        • Chercheur principal:
          • Kymble Spriggs, MBBS MPH FRACP FRCP FAAAAI

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Eligibility criteria

- Any adult (≥ 18 years) who has completed a JJA VIT program at one of the three participating sites.

Inclusion Criteria:

  1. Completed a continuous program of JJA VIT of between 3 and < 6 years duration.
  2. Have ceased JJA VIT for ≥ 18 months but < 5 years.
  3. Have the ability to provide informed consent.

Exclusion Criteria:

  1. Any person < 18 years.
  2. Any adult (≥ 18 years) who has not completed a continuous JJA VIT program of duration between 3 and < 6 years.
  3. Any adult (≥ 18 years) who has completed a continuous JJA VIT program of duration between 3 and < 6 years but ceased JJA VIT < 18 months or > 5 years ago.
  4. Any person who has a medical condition, that in the opinion of the investigator, may place them at increased risk if they were to have a sting challenge.
  5. Unable to understand study requirements and provide informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Participants qui ont terminé le traitement d'immunothérapie de fourmi jack cavall

Jack Jumper Ant Venom Immunotherapy involves injections, under the skin, of gradually increasing doses of insect venom. The treatment is usually between 3-<6 years duration. Participants will have completed this treatment at least 18 months prior to their enrolment in this trial.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Presence of a systemic reaction to JJA live ant sting challenge
Délai: Periprocedural

This will be assessed by the clinician and recorded as YES or NO.

Periprocedural
Severity of a clinically assessed systemic reaction measured by The Brown Grading Criteria
Délai: Periprocedural

The Brown Grading Criteria measures the severity of anaphylactic reactions by categorizing symptoms based on body systems affected and physiological impact. The tool uses a 3-point grading system: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe. Higher scores indicate more severe anaphylactic reactions.

Periprocedural

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in presence of a systemic reaction to a field sting following cessation of Jack Jumper Ant Venom Immunotherapy as reported by the patient on a trial-specific questionnaire
Délai: At enrolment, 1-month post procedure and annually for 3-years

Trial specific questionnaire to be completed by the patient which captures information about any Jack Jumper Ant stings that the patient may have had since completion of Venom Immunotherapy Treatment and whether or not they experienced any type of reaction. If no sting was experienced only one question is required to be answered. If sting/s was experienced ten questions are asked including timing, symptoms, location, treatment and environment.

At enrolment, 1-month post procedure and annually for 3-years
Change in severity of a systemic reaction to a field sting following cessation of Jack Jumper Ant Venom Immunotherapy as measured by The Brown Grading Criteria
Délai: At enrolment, 1-month post procedure and annually for 3-years

The Brown Grading Criteria measures the severity of anaphylactic reactions by categorizing symptoms based on body systems affected and physiological impact. The tool uses a 3-point grading system: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe. Higher scores indicate more severe anaphylactic reactions.

At enrolment, 1-month post procedure and annually for 3-years
Change in attitude towards adrenaline auto-injectors as measured by the Adrenaline Auto-injector Questionnaire
Délai: At enrolment, 1-month post procedure and annually for 3-years

The Adrenaline Auto-injector Questionnaire measures patient attitudes and behaviors related to adrenaline auto-injectors as a 4 question survey. Current possession of an adrenaline auto-injector (yes/no), decision-making process regarding auto-injector maintenance (doctor advice, personal decision, or other influence), carrying/storage behaviors (ranging from constant carriage to unknown location), overall attitude assessment using a 7-point scale regarding the advantages and disadvantages of carrying an auto-injector where the minimum score is 1 and the maximum score is 7. A lower score indicates a better outcome.

At enrolment, 1-month post procedure and annually for 3-years
Change in quality of life as measured by the Vespid Quality of Life Questionnaire
Délai: At enrolment, 1-month post procedure and annually for 3-years

An adapted insect allergy specific health-related quality of life questionnaire.

14 questions with 7 response options giving a score of 1-7, with lower scores representing a higher quality of life.

At enrolment, 1-month post procedure and annually for 3-years
Change in quality of life measured using the Hospital Anxiety and Depression Scale
Délai: At enrolment, 1-month post procedure and annually for 3-years

Developed to assess depression and anxiety. Each response ranges from 0 to 3, the 14 responses are added to yield a total score between 0 and 42. Higher scores indicate higher severity of anxiety and depression.

At enrolment, 1-month post procedure and annually for 3-years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Adriana Le, MBBS FRACP, Royal Hobart Hospital

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

25 novembre 2025

Achèvement primaire (Estimé)

1 octobre 2029

Achèvement de l'étude (Estimé)

1 octobre 2029

Dates d'inscription aux études

Première soumission

2 avril 2025

Première soumission répondant aux critères de contrôle qualité

13 avril 2025

Première publication (Réel)

20 avril 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

After the data has been cleaned and database has been locked, the de-identified data and if consented, personal identifying information, will be shared to National Allergy Centre of Excellence (NACE) Allergy BioRepository via a safe and secure mechanism, for storage and use in future allergy research.

Délai de partage IPD

At 6 months post the commencement of JAVELIN, de-identified data, encrypted with NACE unique identifier codes and secure linkage key tokens, will be transferred to the ALBI platform, for storage, integration and sharing for future HREC-approved allergy research purposes. Data once in ALBI remains indefinitely.

Critères d'accès au partage IPD

ALBI will only provide researchers with non-identifiable information following the Scientific Access Framework. Researchers need to apply for access to ALBI data. Once approved, data will be made available to the researchers by logging in through a secure research platform. Researchers will not have access to the entire ALBI system as they will be provided extracts from ALBI of non-identifiable information related to their specific request and approval. Information will only be shared with ethically approved future allergy research studies.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • ANALYTIC_CODE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner